Gravity Analytica

Genenta Strengthens Agreement with AGC Biologics to Boost Cell Therapy Manufacturing

GNTA 01.09.2025

SERA-AI Powered Highlights

Drug:TEMF-001 Temferon

Diseases:Metastatic Renal Cell Cancer

Diseases:Glioblastoma Multiforme

Date of Upcoming Event:2025-01-13

Name of Upcoming Event:Biotech Showcase 2025

Date of Upcoming Event:2025-01-15

Name of Upcoming Event:Italy on the Move

Full Press Release SEC Filings Our GNTA Tweets

About Gravity Analytica

Recent Filings

PDF Version

Sharing Insights at the 'Italy on the Move' Event and Engaging Investors at Biotech Showcase During JPM Healthcare Week in San Francisco

MILANandNEW YORK,Jan. 09, 2025(GLOBE NEWSWIRE) --Genenta Science(NASDAQ: GNTA), a pioneer in immuno-oncology and a leader in cell-based therapeutics, is pleased to announce that it has strengthened its partnership withAGC Biologics, a global contract development and manufacturing organization (CDMO), by amending their Development and Master Services Agreement. This amendment introduces anexclusive GMP suite at the AGC Biologics Cell andGene Center of ExcellenceinMilan, dedicated to the manufacturing of Genenta’s cell therapy product, ensuring compliance with cGMP standards. This strategic move enhances Genenta’s production capabilities, potentially improving efficiency and reliability in its manufacturing processes.

The newly approved methastatic Renal Cell Cancer (mRCC) Phase 1/2a trial began in Q4 2024, and Genenta expects to treatsix patients by the end of the first half of 2025, while continuing progress with the Glioblastoma Multimforme (GBM) study. In total, Genenta projects manufacturing27 autologous drug productsin 2025.

"Our strengthened partnership withAGC Biologicsrepresents our unwavering commitment to patients participating in our GBM and mRCC trials," saidPierluigi Paracchi, CEO and Co-founder of Genenta. "This enhanced capacity ensures that we can treat a larger number of patients and further validate our therapeutic approach, bringing us closer to our vision of transforming cancer treatment through cell-based therapies."

Prof.Luigi Naldini, Co-founder of Genenta, noted: "Our recent preclinical and clinical studies underscore Temferon’s unique potential to reprogram the tumor microenvironment, inhibiting myeloid cell-induced immune suppression and fostering T-cell responses. This approach not only enhances the potential efficacy of Temferon as a monotherapy but also suggests promising synergies when combined with various immunotherapeutic strategies, including immune checkpoint inhibitors and CAR-T cell therapies. These findings provide a strong foundation for advancing therapeutic strategies targeting solid tumors and bring us closer to open up new cancer treatments."

Upcoming Engagements duringJPM Healthcare Week: Genenta will participate inBiotech Showcase 2025, taking placeJanuary 13–15,2025, inSan Franciscoto present its innovative technology for treating solid tumors through genetically modified cell therapy. Pierluigi Paracchi will also speak at"Italyon the Move”,a flagship biotech event organized by theItalian Ministry of Foreign Affairs and International Cooperation. The event, aimed at promoting Italy’s life sciences sector and fostering international investments, will be held onJanuary 15,2025, at INNOVIT – Italian Innovation and Culture Hub inSan Francisco. Notable speakers includeKarthic Jayaraman, Partner and Co-Head ofGlobal HealthcareatTPG Capital, andFrederick Beddingfield, CEO of Rubedo Life Sciences. The event will be moderated byAudrey Greenberg, Co-Founder and Executive Managing Director of theCenter for Breakthrough Medicines.

About GenentaGenenta (Nasdaq: GNTA) is a clinical stage immuno-oncology company developing a proprietary hematopoietic stem cells therapy for the treatment of a variety of solid tumor cancers. Genenta's first in class product candidate is TemferonTM, which is designed to allow the expression of immune-therapeutic payloads within the tumor microenvironment by bone marrow derived myeloid cells and enable a durable and targeted response. Genenta has completed a Phase 1 trial for newly diagnosed Glioblastoma Multiforme patients with an unmethylated MGMT gene promoter, which suggests the potential reprogramming of the tumor microenvironment and inhibiting of myeloid induced tolerance, while allowing the induction of T cell responses, potentially breaking immune tolerance. Genenta has initiated in Q4 2024 a Phase 1/2a metastatic Renal Cell Carcinoma study that will also include combination with immune checkpoint inhibitors. Our treatments are designed as one-time monotherapies, but with the additional potential, when used in combination, to significantly enhance the efficacy of other approved therapeutics.

Forward-Looking StatementsStatements in this press release contain “forward-looking statements,” within the meaning of theU.S.Private Securities Litigation Reform Act of 1995, that are subject to substantial risks and uncertainties. All statements, other than statements of historical fact, contained in this press release are forward-looking statements. Forward-looking statements contained in this press release may be identified by the use of words such as “anticipate,” “believe,” “contemplate,” “could,” “estimate,” “expect,” “intend,” “seek,” “may,” “might,” “plan,” “potential,” “predict,” “project,” “suggest,” “target,” “aim,” “should,” “will,” “would,” or the negative of these words or other similar expressions, although not all forward-looking statements contain these words. Forward-looking statements are based on Genenta’s current expectations and are subject to inherent uncertainties, risks and assumptions that are difficult to predict, including risks related to the completion and timing of its ongoing clinical trial for newly diagnosed GBM patients with uMGMT-GBM, its expected clinical trial for metastatic RCC or any related studies, as well as Genenta’s ability to fund its research and development plans. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate. These and other risks and uncertainties are described more fully in the section titled “Risk Factors” in Genenta's Annual Report on Form 20-F for the year endedDecember 31, 2023filed with theSecurities and Exchange Commission. Forward-looking statements contained in this announcement are made as of the date of this announcement, and Genenta undertakes no duty to update such information except as required under applicable law.

This press release discusses product candidates that are under preclinical or clinical evaluation and that have not yet been approved for marketing by theU.S. Food and Drug Administrationor any other regulatory authority. Until finalized in a clinical study report, clinical trial data presented herein remain subject to adjustment as a result of clinical site audits and other review processes. No representation is made as to the safety or effectiveness of these product candidates or the use for which such product candidates are being studied. TemferonTM is an investigational product candidate for which the effectiveness and safety have not been established. In addition, TemferonTM is not approved for use in any jurisdiction.

Genenta MediaTiziana Pollio, Mobile: +39 348 23 15 143Email:tiziana.pollio@genenta.com

Source: GENENTA SCIENCE SPA

Please be aware that the following content has been generated by an AI system and may contain errors, inconsistencies, or outdated information. It is provided as-is without any warranties or guarantees of accuracy. We strongly recommend using this content as a starting point for further research and consultation with relevant experts or authorities. We disclaim any liability for damages or losses resulting from the use or reliance on this content.Please note that this is a beta version of the Gravity Analytica LLC’s AI Service which isstill undergoing final testing before its official release. Theplatform, its software and all content found on it are provided on an“as is” and “as available” basis. Gravity Analytica LLC does not give any warranties,whether express or implied, as to the suitability or usability of thisservice, webpage, or its software or any of its content.Should you encounter any bugs, glitches, lack of functionality orother problems on the website, please let us know immediately so wecan rectify these accordingly. Your help in this regard is greatlyappreciated! You can write to us at this addressteam@gravityanalytica.com